“At the recent TD Cowen 46th Annual Health Care Conference, BioMarin Pharmaceutical executives outlined a refreshed corporate strategy focused on integrating key acquisitions, defending its lead in achondroplasia treatment with Voxzogo amid emerging competition, and targeting a 40% non-GAAP operating margin in 2026, excluding impacts from the pending Amicus Therapeutics deal. The presentation highlighted operational efficiencies from a completed cost transformation program and confidence in sustained growth across core franchises despite competitive pressures.”
BioMarin Pharmaceutical Outlines Strategic Path Forward at TD Cowen Conference
BioMarin Pharmaceutical executives took the stage at the TD Cowen 46th Annual Health Care Conference to provide a comprehensive update on the company’s direction. CEO Alexander Hardy, who has led a strategic refresh since taking the helm, emphasized the evolution of the company’s approach following a detailed review completed in recent years. This refresh has refined priorities around rare disease therapies, with a sharpened focus on genetically defined conditions and sustainable profitability.
A core element of the discussion was the integration of recent strategic moves, including the acquisitions of Inozyme Pharma and the pending $4.9 billion purchase of Amicus Therapeutics. These deals are expected to bolster the pipeline and commercial portfolio in rare diseases. The Amicus transaction, anticipated to close in the second quarter of 2026, involves two approved therapies that add complementary assets to BioMarin’s offerings. While the deal introduces some near-term dilution—primarily from integration costs and financing-related interest expenses—management projects it will become accretive within the first 12 months post-close and substantially accretive by 2027.
On the profitability front, BioMarin reiterated its commitment to reaching approximately 40% non-GAAP operating margin in 2026 for its organic business, excluding any contribution from Amicus. This target builds on the successful execution of a $500 million cost transformation program that has streamlined operations and enhanced efficiency. The margin goal reflects disciplined expense management, improved gross margins from scale in key products, and ongoing operational excellence across manufacturing and commercial activities.
Voxzogo (vosoritide), the company’s flagship growth driver for achondroplasia, received significant attention. The treatment has delivered robust performance, with full-year 2025 revenues showing 26% year-over-year growth, driven by expanded penetration in over 55 commercial markets and increasing demand among eligible patients. Management provided 2026 revenue guidance for Voxzogo in the range of $975 million to $1.025 billion, pointing to continued high single-digit growth at the midpoint.
However, the competitive landscape for achondroplasia treatments is intensifying. Voxzogo, as the first and currently only approved therapy in this space, faces potential challenges from several late-stage candidates. Key competitors include:
Ascendis Pharma’s TransCon CNP, a once-weekly C-type natriuretic peptide analog with an NDA under FDA review and a potential decision in late 2025.
BridgeBio Pharma’s infigratinib, an oral FGFR3 inhibitor that recently reported positive late-stage data showing improved annualized height velocity in children with achondroplasia.
Other emerging programs exploring different mechanisms.
BioMarin executives expressed preparedness for this competition, stressing the long-term durability and established safety profile of Voxzogo. They noted that any switching among treatments would likely be complex and gradual due to the chronic nature of the condition, the need for long-term data on efficacy and safety, and the established real-world experience with Voxzogo. The company is also advancing its own next-generation efforts, including BMN 333, a longer-acting CNP candidate showing promising early results that could extend dosing intervals and maintain leadership.
Beyond Voxzogo, the enzyme therapies franchise—anchored by products like Palynziq—continues to perform solidly, with 2025 growth of 9% and projected 2026 revenues of $2.225 billion to $2.275 billion. Overall 2026 revenue guidance stands at $3.325 billion to $3.425 billion (excluding Amicus), with non-GAAP diluted EPS expected in the $4.95 to $5.15 range. These figures account for lower contributions from legacy assets like Roctavian royalties and Kuvan.
The presentation also touched on portfolio optimization, including plans to divest or wind down certain non-core elements to focus resources on high-potential opportunities. An ongoing ITC case related to intellectual property was mentioned, with a preliminary decision anticipated in August.
Overall, BioMarin’s messaging at the conference underscored resilience and proactive positioning: leveraging acquisitions for diversified growth, protecting Voxzogo’s market position through clinical and commercial strength, and delivering on profitability commitments via cost discipline and scale.
Disclaimer: This article is for informational purposes only and does not constitute investment advice, financial recommendations, or an endorsement of any security. Readers should conduct their own research and consult qualified professionals before making investment decisions.
Leave a Reply